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http://www.biomedcentral.com/1471-2393/13/161RESEARCH ARTICLE Open AccessComparison of placental growth factor and fetal
flow Doppler ultrasonography to identify fetal
adverse outcomes in women with hypertensive
disorders of pregnancy: an observational study
Attila Molvarec*, Nóra Gullai, Balázs Stenczer, Gergely Fügedi, Bálint Nagy and János Rigó JrAbstract
Background: Hypertensive disorders of pregnancy and intrauterine growth restriction (IUGR) are leading causes of
maternal and perinatal morbidity and mortality. Failure to detect intrauterine growth restriction in women at high
risk has been highlighted as a significant avoidable cause of serious fetal outcome. In this observational study we
compare fetal flow using Doppler ultrasonography with a new test for placental growth factor (PlGF) to predict
fetal adverse events.
Methods: Eighty-nine women with hypertensive disorders of pregnancy (24 with chronic hypertension, 17 with
gestational hypertension, 12 with HELLP syndrome, 19 with preeclampsia and 17 with superimposed preeclampsia)
were enrolled. A single maternal blood sample to measure free PlGF (Alere Triage) taken before 35 weeks of
pregnancy was compared to the last Doppler ultrasound measurement of fetal flow before delivery. PlGF was
classified as normal (PlGF≥100 pg/ml), low (12<PlGF<100) or very low (PlGF≤12 pg/ml). A positive test for abnormal
fetal flow was defined as either signs of centralisation of the fetal circulation or diastolic block or reverse flow in the
umbilical artery or descending aorta; this was a criterion for delivery. Fetal outcomes were intrauterine growth
restriction and birth before 37 weeks of pregnancy.
Results: In total 61/89 women had a preterm birth and 22 infants had IUGR. Of those who delivered preterm,
20/20 women with abnormal fetal flow and 36/41 (87.8%) women with normal fetal flow had low or very low PlGF.
Of those infants with IUGR, 22/22 had low or very low maternal PlGF and 10/22 had abnormal fetal flow.
Conclusions: PlGF may provide useful information before 35th gestational week to identify fetuses requiring urgent
delivery, and those at risk of later adverse outcomes not identified by fetal flow Doppler ultrasonography.
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Hypertensive disorders are one of the most common
complications of pregnancy, with a prevalence of 6–22%
[1,2]. These conditions are responsible for the majority
of maternal and perinatal morbidity and mortality, in-
cluding intrauterine growth restriction (IUGR). A recent
study has shown that unrecognised IUGR is the single
largest risk factor to pregnancies that end in stillbirth
[3]. Research focus is now on improving antenatal* Correspondence: molvarec@freemail.hu
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reproduction in any medium, provided the ordetection of fetuses at risk, to allow selective mana-
gement, timely delivery and minimisation of serious
outcomes.
Placental growth factor (PlGF) is a member of the
vascular endothelial growth factor (VEGF) family. It is
produced mainly by the placenta, and has potent pro-
angiogenic effects. In normal uncomplicated pregnancy,
PlGF levels rise until approximately pregnancy week 32
and then fall until delivery [4]. In pregnancies compli-
cated by preeclampsia before the 37th week with or with-
out IUGR, PlGF levels are significantly lower [5].al Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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angiogenic factor levels in maternal peripheral blood in
the prediction and diagnosis of preeclampsia has been
extensively studied in recent years [6-20]. We recently
added to the limited information available about the
levels of these factors in other forms of hypertension in
pregnancy [21-24] and found that free PlGF measured
before 35 weeks of pregnancy may predict preterm deli-
very in all forms of hypertensive disorders of pregnancy
[25]. There is still little information to date on their abil-
ity to predict fetal outcomes such as intrauterine growth
restriction through their assessment of placental func-
tion [26].
In this study, we used a new method, the Alere Triage®
PlGF test, for measuring free PlGF levels in the peri-
pheral blood of hypertensive pregnant women before
the 35th gestational week of pregnancy. We examined its
prognostic efficiency regarding adverse fetal outcomes in
all forms of hypertensive disorders of pregnancy, com-
pared with currently recommended assessment of fetal
wellbeing.
Methods
In this observational study, 89 women with hypertensive
disorders of pregnancy (19 women with preeclampsia,
12 with hemolysis, elevated liver enzymes and low plate-
let count (HELLP) syndrome, 17 with superimposed pre-
eclampsia (SIPE), 24 with chronic hypertension, and 17
with gestational hypertension) were enrolled. The study
subjects were selected from the previously reported
groups of hypertensive pregnant women [25] based on
availability of Doppler ultrasound results. All subjects
were Caucasian and resided in the same geographic
area. Blood samples were taken in the First Department
of Obstetrics and Gynecology, Semmelweis University,
Budapest, Hungary between May 2008 and October 2010.
The blood draw occurred between the 22nd and 34th com-
pleted gestational week at the time of the first routine
clinical blood test and repeated only if women were re-
classified. An interview was carried out with every sub-
ject after the diagnosis and again 12 weeks after the
delivery, and if necessary, reclassification was done in-
dependently of the PlGF level. All subjects gave written
informed consent prior to the involvement in the study.
The study protocol was approved by the Regional and
Institutional Committee of Science and Research Ethics
of the Semmelweis University (TUKEB 52/2008). The
study was conducted in accordance with the Declaration
of Helsinki.
Hypertension was diagnosed if systolic blood pressure
(BP) was ≥140 mmHg, or diastolic BP ≥90 mmHg, on
two occasions, six hours apart. According to the defi-
nitions of the ACOG and NHBPEP we classified the sub-
jects’ diagnoses into four groups: chronic hypertension,gestational hypertension, preeclampsia, and superim-
posed preeclampsia. We separately categorised any wo-
men with hypertension, proteinuria and the syndrome of
hemolysis, elevated liver enzymes and low platelet count
as HELLP.
Chronic hypertension was diagnosed if high blood
pressure developed prior to pregnancy or before the 20th
week of gestation, or if hypertension persisted for more
than 12 weeks postpartum. Gestational hypertension was
applied to women who developed new-onset hyperten-
sion after the 20th week of gestation, in the absence of
proteinuria, confirmed after delivery. Patients who later
progressed to preeclampsia were excluded from this
group, and following repeated blood draw, they were in-
cluded in the pre-eclamptic group. Preeclampsia was de-
fined as hypertension and proteinuria (≥ 300 mg / 24
hours, or ≥+ by urine dipstick) with an onset after the 20th
gestational week. Severe preeclampsia was diagnosed if
one of the following occurred: systolic BP ≥160 mmHg,
diastolic BP ≥110 mmHg, proteinuria ≥5000 mg per 24
hours or ≥+++ by urine dipstick, partial HELLP syndrome,
signs of renal insufficiency, pulmonary edema or threa-
tening eclampsia. The diagnosis of HELLP syndrome was
made based on characteristic laboratory findings (platelet
count <150 G/l, SGOT and SGPT>70 U/l, LDH>600 U/l).
All of the subjects in this group also met the criteria
for severe preeclampsia. Subjects with chronic hyper-
tension who developed proteinuria after 20 weeks of ges-
tation were categorised as superimposed preeclampsia.
Subjects with preeclampsia, superimposed preeclampsia
or HELLP syndrome were further grouped into early-
onset (disease onset before 34th completed gestational
week). Women with multiple gestations were not enrolled
in this study.
A newborn was considered small for gestational age
(SGA) if the birth weight was below the 10th percentile
for gestational age and gender, according to a Hungarian
birth weight percentile table. All neonates with SGA
had an asymmetric size (normal length, but low weight
for gestational age at delivery), indicating that they had
intrauterine growth restriction and were not constitu-
tionally small. In addition, none of them had fetal
structural abnormalities or genetic diseases. For the
determination of the abnormalities of fetal circulation
we evaluated the last Doppler ultrasound results prior
to delivery. Blood flow was examined in the umbilical
and in the fetal middle cerebral arteries, as well as in
the descending aorta of the fetus. Abnormal fetal flow
was diagnosed if diastolic block or reverse flow in the
umbilical artery or descending aorta, or if signs of the
centralisation of the fetal circulation (increased resis-
tance in the umbilical artery and/or descending aorta
with decreased resistance in the middle cerebral artery)
were present.
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section, as clinically required, for women at any gesta-
tional age with HELLP syndrome, severe uncontrollable
hypertension, severe proteinuria, with signs of renal
insufficiency, pulmonary edema, threatening eclampsia
(persistent headache and visual disturbance), low platelet
count (< 100 000 /μl), elevated liver enzymes (SGOT>
70 U/l) with epigastric pain, or evidence of fetal com-
promise (abnormal fetal flow or pathological CTG), se-
vere IUGR or severe oligohydramnios. In the absence of
any of these factors, we continue conservative manage-
ment until the 37th completed gestational week.
After each blood draw, the EDTA-anticoagulated
plasma samples were immediately centrifuged at 3000 g
for 10 min at 4°C and the supernatants were kept frozen
at −80°C until assayed. Plasma was analysed for free
PlGF using the Alere Triage® PlGF assay according to
the manufacturer’s instructions. Using fluorescently-
labelled monoclonal antibodies against PlGF for PlGF
quantification, this immunoassay is run with a single-use
disposable plastic assay test cartridge in conjunction
with the Triage Meter. Briefly, 250 microliter of thawed
plasma (room temperature) is pipetted into the sample
port of a new test cartridge. The cartridge is inserted
into the meter and results are displayed in approximately
15 minutes in pg/ml. The cartridge contains chemistries
for on-board positive and negative control systems.
Control systems at the level of the cartridge and meter
ensure that the quantitative PlGF result is valid. Calibra-
tion information is supplied by the manufacturer in the
form of a lot-specific EPROM chip that is contained
within each kit of devices. The measurable range of the
assay is 12–3000 pg/ml. Concentrations below 12 pg/ml
are value assigned based on the calibration curve, but
this value is displayed to the user as a qualitative result
“<12 pg/ml”. Women were tested up to 34 completed
weeks, as recommended in the manufacturer’s product
insert. The intra/ inter-assay coefficients of variation at
mean concentrations of 85.2 and 1300 pg/ml were 12.1/
12.8% and 11.7/13.2%, respectively.
Although PlGF concentrations fluctuate during preg-
nancy [4,27], original cut-off levels based on the 5th per-
centile of a PlGF level in a normal healthy pregnant
population do not differ significantly from an absolute
threshold of 100 pg/ml in women presenting with signs
and symptoms of preeclampsia before the 35th week of
pregnancy [Chappell et al., personal communication,
submitted for publication, see Appendix for full list of
researchers]. Therefore levels were classified as normal
(PlGF≥100 pg/ml), low (12 pg/ml<PlGF<100 pg/ml) or
very low (PlGF≤12 pg/ml).
Descriptive statistics were used to present the cli-
nical characteristics. Outcomes were broken out into
three PlGF groups and abnormal/ normal fetal flow,as described above. All statistical analyses were con-
ducted using the MATLAB version 8.0. P-values were
calculated using a two-tailed Fisher Exact test of each
2 × 2 contingency table (in this case a single PlGF
cut-off of 100 pg/ml was used).
Results
In total 89 women with hypertensive disorders of preg-
nancy were recruited into the study. The demographics
and clinical characteristics of the study participants are
presented in Table 1.
By outcome, 61/89 women had a preterm birth and 22
neonates had IUGR. Table 2 shows the results of the
fetal flow and PlGF tests by outcome (preterm birth and
IUGR) and by diagnoses. All 20 women with abnor-
mal fetal flow had a PlGF<100 pg/ml so that the over-
all concordance between fetal flow and PlGF was high
(p-value=0.0023, two tailed Fisher Exact test of the
contingency table dividing the 89 women by PlGF and
fetal flow).
Considering the PlGF test results for the 28 women
who had both a term birth and an infant of normal birth
weight, 1/1 woman with preeclampsia, 2/3 women with
SIPE, 9/11 women with GHT and 5/13 women with
CHT had a normal PlGF result. All of these women had
a normal fetal flow.
Table 3 shows PlGF test results in women with normal
and abnormal fetal flow. Of those who delivered pre-
term, 20/20 women with abnormal fetal flow and 36/41
women with normal fetal flow had low or very low PlGF.
Five women who had a preterm delivery had both a nor-
mal fetal flow and a normal PlGF test; of these five, 2
women had an early delivery because of premature rup-
ture of membranes. All 5 women had infants with a nor-
mal birth weight. Of the IUGR neonates, 22/22 had low
or very low maternal PlGF and 10/22 had abnormal fetal
flow. In the subset of 69 women who had normal fetal
flow, a positive PlGF test result was significantly asso-
ciated with adverse fetal outcomes (p-value<0.0001 for
preterm delivery and p-value=0.0069 for IUGR).
Twenty-four of our study participants had pathological
CTG, 21 of whom had low or very low PlGF. Oligohy-
dramnios occurred in 27 cases, 20 of them had low or
very low PlGF. Of those who delivered preterm, 19/20
women with pathological CTG and 37/41 women with
normal CTG had low or very low PlGF. In the pre-
term delivery group, 19/21 women with oligohydram-
nios and 37/40 women with normal amniotic fluid
volume had low or very low PlGF. In the subset of 41
women with preterm delivery and normal fetal flow,
10/11 women with pathological CTG and 11/13 wo-
men with oligohydramnios had low or very low PlGF.
Of the 22 IUGR neonates, 10 had pathological CTG
and 10 had oligohydramnios.
Table 1 Demographics and clinical characteristics (N=89)
Diagnosis All (N=89) GHT (n=17) CHT (n=24) PE (n=19) HELLP (n=12) SIPE (n=17)
Maternal age (years) 33 (30–36) 34 (33–35) 33 (30–37) 33 (27–37) 30 (29–33) 34 (32–36)
Pre-gestational BMI (kg/m2) 26.2 (23.1–33.1) 26.2 (23.1–30.8) 30 (25.9–36.2) 25.6 (22.4–29.7) 29.8 (23.7–35.5) 24.4 (21.9–30)
Primiparous women (%) 51 (57.3) 11 (64.7) 12 (50) 11 (57.9) 9 (75) 8 (47.1)
Current smoking (%) 7 (7.9) 0 (0) 2 (8.3) 1 (5.3) 2 (16.7) 2 (11.8)
Previous history of PE (%) 12 (13.5) 1 (5.9) 3 (12.5) 3 (15.8) 2 (16.7) 3 (17.6)
GA at blood draw (weeks) 32 (28–33) 33 (31–34) 33 (31–34) 30 (28–33) 29 (27–32) 31 (28–32)
GA at delivery (weeks) 34 (30–37) 38 (36–39) 37 (34–38) 31 (28–34) 29 (27–32) 32 (30–36)
Blood draw to delivery time
interval (days)
8 (1–29) 29 (24–51) 20 (4–43) 1 (0–3) 1 (0–2) 8 (3–25)
Fetal birth weight (grams) 1900 (1150–3100) 3330 (2690–3860) 2700 (2105–3360) 1220 (990–1770) 1125 (845–1420) 1750 (1100–2560)
Fetal birth length (cms) 45 (39–52) 51 (48–55) 51 (45–53) 40 (37–45) 39 (36–44) 45 (40–51)
Preterm birth (%) 61 (68.5) 6 (35.3) 11 (45.8) 18 (94.7) 12 (100) 14 (82.4)
IUGR (%) 22 (24.7) 3 (17.6) 2 (8.3) 8 (42.1) 4 (33.3) 5 (29.4)
Early-onset PE (%) 44 (49.4) 0 (0) 0 (0) 17 (89.5) 11 (91.7) 16 (94.1)
Severe PE (%) 41 (46.1) 0 (0) 0 (0) 18 (94.7) 12 (100) 11 (64.7)
C-Section (%) 78 (87.6) 12 (70.6) 19 (79.2) 19 (100) 12 (100) 16 (94.1)
Continuous variables are reported as Median (IQR) and categorical variables are reported as n (%), where percent is relative to the column total. Gestational
hypertension (GHT); chronic hypertension (CHT); preeclampsia (PE); hemolysis, elevated liver enzymes and low platelet count syndrome (HELLP); superimposed
preeclampsia (SIPE); body mass index (BMI); gestational age (GA); intrauterine growth restriction (IUGR); Cesarean section (C-section).
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This study aimed to assess the performance of the Alere
Triage® PlGF test, a rapid test for measuring PlGF levels
in the maternal peripheral blood. Our study population
consisted of women with chronic hypertension, gesta-
tional hypertension, HELLP syndrome, preeclampsia and
superimposed preeclampsia. We earlier evaluated the
diagnostic accuracy of this test in the study groups and
healthy pregnant control subjects [25] and found that
using a gestational age-dependent threshold of 5% of a
normal population, a positive PlGF test predicted deliv-
ery before 37 weeks in over 90% of hypertensive women.Table 2 Results of PlGF and fetal flow tests, by outcome and
Normal PlGF
Fetal flow Normal Abnormal Nor
n 22 0 2
Percent of N (24.7) 0.0 (25
Preterm 5 (22.7) 14 (6
IUGR 0 (0.0) 3 (1
CHT 8 (36.4) 11 (4
GHT 10 (45.5) 3 (1
HELLP 0 (0.0) 2 (8
PE 1 (4.5) 2 (8
SIPE 3 (13.6) 5 (2
Breakout of N=89 subjects by three placental growth factor test result groups (norm
groups (abnormal, normal). The breakout by outcomes (preterm birth, IUGR infant)
Intrauterine growth restriction (IUGR); chronic hypertension (CHT); gestational hype
syndrome (HELLP); preeclampsia (PE); superimposed preeclampsia (SIPE).In this study we compared the diagnostic value of PlGF
measured before 35 weeks using two absolute thresholds
with the last Doppler ultrasonography before delivery in
identifying preterm birth and IUGR neonates.
We found that PlGF concentration below 100 pg/ml
identified all women with hypertensive disorders of preg-
nancy who required urgent delivery following an abnor-
mal fetal flow result, and predicted all IUGR neonates,
and 56/61 women who had a preterm delivery. Nearly
60% of women with normal fetal flow results had a pre-
term delivery. Our protocol for delivery dictated birth by
Cesarean section, as clinically required, for women atdiagnosis (N=89)
Low PlGF Very Low PlGF
mal Abnormal Normal Abnormal
3 3 24 17
.8) (3.4) (27.0) (19.1)
0.9) 3 (100.0) 22 (91.7) 17 (100.0)
3.0) 3 (100.0) 9 (37.5) 7 (41.2)
7.8) 0 (0.0) 2 (8.3) 3 (17.6)
3.0) 1 (33.3) 2 (8.3) 1 (5.9)
.7) 0 (0.0) 6 (25.0) 4 (23.5)
.7) 1 (33.3) 10 (41.7) 5 (29.4)
1.7) 1 (33.3) 4 (16.7) 4 (23.5)
al PlGF≥100, low 12<PlGF<100, and very low PlGF≤12) and two fetal flow
and diagnosis shows the number and percent (relative to n) for each category.
rtension (GHT); hemolysis, elevated liver enzymes and low platelet count
Table 3 Adverse fetal outcomes by fetal flow (abnormal, normal) and PlGF (normal, low, very low) results (N=89)
Abnormal fetal flow Normal fetal flow
PlGF Very Low Low Normal Very Low Low Normal
n 17 3 0 24 23 22
Percent of N 19.1 3.4 0.0 27.0 25.8 24.7
Preterm 17 (100.0) 3 (100.0) 22 (91.7) 14 (60.9) 5 (22.7)
p-value <0.0001
IUGR 7 (41.2) 3 (100.0) 9 (37.5) 3 (13.0) 0 (0.0)
p-value 0.0069
Breakout of N=89 subjects by three placental growth factor groups (normal is PlGF≥100, low is 12<PlGF<100, and very low is PlGF≤12) and fetal flow (abnormal
vs normal). The breakout by preterm delivery and IUGR shows the number and percent (relative to n) for each category. The p-values are from a two-tailed Fisher
Exact test of the 2×2 contingency table (with PlGF Low and Very Low grouped together) for each outcome (preterm and IUGR) in the subset with normal
fetal flow.
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including abnormal fetal flow, pathological CTG and se-
vere oligohydramnios. The Triage PlGF test identified
the majority of women with normal fetal flow who
needed to be delivered preterm due to pathological CTG
or oligohydramnios. Considering both test results to-
gether, no woman with a normal fetal flow and normal
PlGF had an IUGR infant, and only 5 had a preterm de-
livery, 2 of whom were due to premature rupture of
membranes.
In a small study Benton et al. [28] found that Triage
PlGF differentiated placental IUGR from constitutionally
small fetuses with a sensitivity of 100% and a specificity
of 86%. Consistently, all of our SGA neonates were
asymmetrically small with no fetal structural abnormal-
ities or genetic diseases suggesting placental IUGR and
had low or very low PlGF. In 2007 Schlembach et al.
[29] correlated levels of angiogenic growth factors, in-
cluding PlGF, with Doppler ultrasound parameters in
women with preeclampsia and intrauterine growth re-
striction (suspected by ultrasound measurements and
confirmed by birth weight). Maternal levels of PlGF were
inversely correlated with PI values in both the umbilical
and uterine arteries. PlGF levels in the umbilical vein
were below the detection limit in nearly all samples of
IUGR fetuses and lower than in those with preeclampsia
(p<0.001). In our study, we observed low or very low
PlGF even in hypertensive women with normal fetal flow
and an IUGR neonate.
Taylor et al. reported in 2003 that maternal circulating
PlGF levels in preeclampsia are lower if accompanied by
IUGR [11]. Furthermore they showed that in normoten-
sive subjects with IUGR, PlGF concentrations are also
decreased compared to controls. Our knowledge about
IUGR in chronic and gestational hypertension in this
regard is deficient. We found a positive PlGF test in all
women with an abnormal fetal flow, all women with an
IUGR neonate, the majority of women with pathological
CTG or oligohydramnios, as well as in a high proportion
of women carrying normal-size fetuses, many of whomhad preterm delivery. Thus, the sensitivity of the PlGF
test for fetal risk (IUGR, abnormal fetal flow, patho-
logical CTG, oligohydramnios, preterm delivery) in the
hypertension group with and without proteinuria was
excellent.
The potential clinical impact of these findings is that
PlGF may provide useful information before 35th gesta-
tional week to identify fetuses requiring urgent delivery,
and those at risk of later adverse outcomes not identified
by fetal flow Doppler ultrasonography. Similarly, for all
women with hypertensive disorders of pregnancy, a
combination of a normal fetal flow and normal PlGF test
may identify women at lower risk of adverse outcomes.
However, the weakness of our study is its retrospective
observational design following normal clinical practice
and the low case number. Additionally, we did not mea-
sure circulating levels of anti-angiogenic factors (sFlt-1,
soluble endoglin). In this retrospective observational
study of a specific target population we are unable to
calculate the specificity of either test with respect to
preterm delivery or IUGR infant, or to calculate nega-
tive or positive predictive values. There is a need for
prospective studies to prove the safety and efficiency
of the test in the clinical management of hypertension
in pregnancy.Conclusions
The Triage test is a quick reliable method for measuring
circulating levels of free PlGF. The test may provide use-
ful information before 35th gestational week to identify
fetuses requiring urgent delivery, and those at risk of
later adverse outcomes not identified by fetal flow Doppler
ultrasonography.Ethical approval
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